Changes and prognostic evaluation of thyroid hormone，troponin I and B-type natriuretic peptide levels in patients with acute coronary syndrome

Abstract

Abstract: Objective　To observe the changes of serum levels of thyroid hormone（TH），cardiac troponin I（cTnI） and B-type natriuretic peptide（BNP） levels in patients with acute coronary syndrome（ACS） during the hospitalization period，and to study the relationship with major adverse cardiovascular events（MACE）. Methods　A total of 120 ACS patients were enrolled randomly and classified into 3 groups including ST-segment elevation acute myocardial infarction（STEMI），non-ST-segment elevation acute myocardial infarction（NSTEMI） and unstable angina（UA） according to the styles of ACS. According to the patients whether occurred MACE or notduring the hospitalization period，2 groups including MACE（＋） and MACE（－） were classified. TH，cTnI and BNP levels were observed respectively. Results　The levels of total triiodothyronine（TT3） in NSTEMI group and STEMI group were significantly lower than thatof UA group（P＜0.05，P＜0.01）. The free triiodothyronine（FT3） level in NSTEMI group was significantly lower than those in STEMI and UA groups（P＜0.05）. The levels of TT3 andfT3 in MACE（＋）group were significantly lower than those in MACE（－）group（P＜0.01）. The levels of cTnI in STEMI and NSTEMI groups were higher than thatin UA group（P＜0.01）.The levels of cTnI in NSTEMI group were higher than those in STEMI group（P＜0.05），but no statistical significance was found between MACE（＋） and MACE（－） groups（P＞0.05）. Thyroid stimulating hormone（TSH），total tetraiodothyronine（TT4） and free tetraiodothyronine（FT4） and BNP levels had no statistical significance both in STEMI，NSTEMI and UA groups and in MACE（＋） and MACE（－） groups（P＞0.05）. The positive rates of cTnI and BNP had no statistical significance between MACE（＋） and MACE（－） groups（P＞0.05）. Conclusions　MACE occurs commonly in the ACS patients with low TT3 andfT3 levels during the hospitalization period. The levels of cTnI and BNP have no significance in the MACE for the ACS patients during the hospitalization period and still are needed further research and study.

Key words: Thyroid hormone, Troponin I, B-type natriuretic peptide, Acute coronary syndrome

TANG Xin，LI Yongshu，JIA Kegang. Changes and prognostic evaluation of thyroid hormone，troponin I and B-type natriuretic peptide levels in patients with acute coronary syndrome[J]. , 2012, 27(12): 1054-1057.

References

[1]Luepker RV，ApplefS，Christenson RH，et al. Case definitionsfor acute coronary heartdisease in epidemiology and clinical research studies：a statementfrom the AHA council on epidemiology and prevention；AHA statistics committee；world heartfederation council on epidemiology and prevention；the European society of cardiology working group on epidemiology and prevention；centersfor disease control and prevention；and the national heart，lung，and blood institute[J]. Circulation，2003，108（20）：2543-2549.
[2]高润霖，吴宁，胡大一，等.心血管病治疗指南和建议[M].北京：人民军医出版社，2006：1-47.
[3]中华医学会心血管学分会，中华心血管病杂志编辑委员会.不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南[J].中华心血管病杂志，2007，35（4）：295-304.
[4]Iltumur K，Olmez G，Ariturk Z，et al. Clinical investigation： thyroidfunction testabnormalities in cardiac arrestassociated with acute coronary syndrome [J]. CritCare，2005，9（4）：R416-R424.
[5]Pimentel RC，Cardoso GP，Escosteguy CC，et al. Throid hormone profile in acute coronary syndromes[J]. Arq Bras Cardiol，2006，87（6）：688-694.
[6]Rodondi N，Aujesky D，Vittinghoff E，et al. Subclinical hypothyroidism and the risk of coronary heartdisease： a meta-analysis[J]. Am J Med，2006，119（7）：541-551.
[7]Sabatine MS，Morrow DA，de Lemos JA，et al. Multimarker approach to risk stratification in non-STelevation acute coronary syndromes： simultaneous assessmentof troponin I，C-reactive protein，and B-type natriuretic peptide[J]. Circulation，2002，105（15）：1760-1763.
[8]James SK，Lindahl B，Siegbahn A，et al. N-terminal pro-brain natriuretic peptide and other risk markersfor the separate prediction of mortality and subsequentmyocardial infarction in patients with unstable coronary artery disease： a global utilization of strategies to open occluded arteries（GUSTO）-Ⅳ substudy[J]. Circulation，2003，108（3）： 275-281.
[9]Lindahl B，Lindbck J，Jernberg T，et al. Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes：afragmin andfastrevascularisation during in stability in coronary artery disease（FRISC）-Ⅱ substudy[J]. J Am Coll Cardiol，2005，45（4）：533-541.
[10]Drewniak W，Snopek G，Zarukiewicz M，et al. Prognostic value of the N-terminal pro-B-type natriuretic peptide in the elderly with acute myocardial infarction[J]. Kardiol Pol，2008，66（7）：750-755.
[11]Valente S，Lazzeri C，Chiostri M，et al. NT-proBNP on admissionfor early risk stratification in STEMI patients submitted to PCI. Relation with extension of STEMI and inflammatory markers[J]. IntJ Cardiol，2009，132（1）：84-89.
[12]莫海泉，罗远标. 急性冠脉综合征血清脂蛋白（a）与肌钙蛋白I的检测意义[J]. 临床医学，2010，30（8）：23-24.
[13]李相磊，邱刚，潘扬，等. 急性冠状动脉综合征患者NT-proBNP界值点的意义[J]. 检验医学，2011，26（1）：16-18.
[14]刘景泉，王淑萍，苏海，等. 心肌钙蛋白I（cTnI）检测在心肌损伤诊断中的应用[J]. 中华临床医学研究杂志，2005，22（11）：3194-3195.

[1]	FU Yi, YANG Xuesong, JIN Ligang, ZHAI Hongli, JIN Xiaoling. Correlation between small and dense low-density lipoprotein cholesterol and acute coronary syndrome with the occurrence of long-term adverse cardiovascular events [J]. Laboratory Medicine, 2023, 38(9): 878-883.
[2]	ZHANG Xin, MA Lijuan. Role of cardiac markers in children [J]. Laboratory Medicine, 2023, 38(6): 505-509.
[3]	YIN Ya, PAN Yuan, ZHOU Hongwei, SHEN Wei. Application progress of BNP and NT-proBNP in neonates [J]. Laboratory Medicine, 2023, 38(6): 518-523.
[4]	LI Li, SUN Haiyan, LI Yuanrui, DOU Min, TANG Wen, JIANG Limin, SHEN Lisong. Changes and clinical roles of perioperative NT-proBNP and PCT in children with congenital heart disease [J]. Laboratory Medicine, 2023, 38(6): 524-531.
[5]	LIU Yanan, XIA Min, HU Shaohua, ZHENG Yue, ZHANG Hong. Roles of lymphocyte subsets，inflammatory factors and NT-proBNP in diagnosis of Kawasaki disease [J]. Laboratory Medicine, 2023, 38(6): 532-537.
[6]	ZHENG Zhiyou, LI Xingzhao, XIE Yage. Changes and clinical significance of HbA_1c，NT-proBNP，Hcy，SOD and TC levels in patients with diabetes cardiomyopathy [J]. Laboratory Medicine, 2023, 38(3): 282-286.
[7]	YAO Hualong. Roles of PTH，CRP，OPG/PYR ratio in elderly patients with osteoporosis [J]. Laboratory Medicine, 2022, 37(12): 1146-1150.
[8]	MA Jianguo, ZHU Xiaolin, DING Yongguang, YIN Meng, LI Hongchun. Predictive values of red blood cell distribution width and myocardial markers for acute myocardial infarction in patients with CAS [J]. Laboratory Medicine, 2022, 37(12): 1164-1168.
[9]	ZHANG Ying, LIU Huiling. Changes of thyroid hormones in patients with COPD and infection and the correlation with low T₃ syndrome [J]. Laboratory Medicine, 2022, 37(11): 1062-1065.
[10]	HE Chengshan, YAO Xiaoyang, JIANG Xiudi, LU Zhicheng. Microarray chemiluminescence immunoassay for quantitative detection of cardiac troponin I autoantibodies and preliminary clinical applications [J]. Laboratory Medicine, 2021, 36(3): 318-324.
[11]	ZHU Chuanxin, ZHOU Yuping, HE Yan, ZHOU Qin. Diagnostic role of NLR,CRP,PCT,DD and NT-proBNP in severe corona virus disease 2019 [J]. Laboratory Medicine, 2021, 36(2): 190-193.
[12]	DU Kun, YAN Jianhua, CHEN Ming, YANG Junyao, ZHANG Guanghui. Role of risk stratification and prognosis of sST2 in acute coronary syndrome patients after percutaneous coronary intervention [J]. Laboratory Medicine, 2021, 36(10): 1020-1025.
[13]	CHEN Hong, LI Jinying, FU Wei. Correlations of serum ferritin,hemoglobin and thyroid hormones in different trimester pregnant women [J]. Laboratory Medicine, 2020, 35(3): 238-242.
[14]	CHEN Bin, LU Weiwei, XU Zhongyu. Roles of serum NT-proBNP,CRP and MMP-9 in children with Kawasaki disease [J]. Laboratory Medicine, 2020, 35(3): 243-246.
[15]	ZHENG Wei, HAO Aijun, ZHU Guoyong, ZHANG Yinhui, WANG Dongyun, PANg Jie. Clinical roles of SAA,CRP,LYMPH#,NT-proBNP and DD in COVID-19 [J]. Laboratory Medicine, 2020, 35(12): 1238-1242.